GlassScriptPhysician profile
Charles King Chan
NPI 1588676134
$3,688.21
in general payments reported to CMS, 2019-2025
16 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $373 · 2021: $955 · 2022: $402 · 2023: $193 · 2024: $863 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.23 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,142.92 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $510.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.83 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $150.23 | 2021-2024 | |
| Gilead Sciences, INC. | $125.17 | 2021-2022 | |
| Lilly USA, LLC | $38.95 | 2019-2024 | Jardiance |
| Stryker Corporation | $34.96 | 2024 | Iconix |
| Amgen INC. | $25.41 | 2023 | Otezla, Repatha |
| Pfizer INC. | $24.12 | 2024 | |
| Horizon Therapeutics Plc | $22.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.82 | 2021 | |
| Novo Nordisk INC | $17.79 | 2023 | Rybelsus |
| Genentech USA, INC. | $15.43 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.45 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.